Reduction in Vancomycin-Resistant Enterococcus and Clostridium difficile Infections following Change to Tympanic Thermometers

1998 ◽  
Vol 19 (5) ◽  
pp. 333-336 ◽  
Author(s):  
Steven Brooks ◽  
Ashraf Khan ◽  
Dorin Stoica ◽  
Jennylyn Griffith ◽  
Les Friedeman ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Vancomycin Resistant Enterococcus ◽  
Vancomycin Resistant

Reduction in Vancomycin-Resistant Enterococcus and Clostridium difficile Infections following Change to Tympanic Thermometers

1998 ◽  
Vol 19 (5) ◽  
pp. 333-336 ◽  
Author(s):  
Steven Brooks ◽  
Ashraf Khan ◽  
Dorin Stoica ◽  
Jennylyn Griffith ◽  
Les Friedeman ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Vancomycin Resistant Enterococcus ◽  
Vancomycin Resistant

scholarly journals Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection

2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Erik R. Dubberke ◽  
Kathleen M. Mullane ◽  
Dale N. Gerding ◽  
Christine H. Lee ◽  
Thomas J. Louie ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Small Sample Size ◽  
Secondary Analysis ◽  
Small Sample ◽  
Vancomycin Resistant Enterococcus ◽  
Recurrent Clostridium Difficile Infection ◽  
Stool Samples ◽  
Vancomycin Resistant

Abstract Background.  Vancomycin-resistant Enterococcus (VRE) is a major healthcare-associated pathogen and a well known complication among transplant and immunocompromised patients. We report on stool VRE clearance in a post hoc analysis of the Phase 2 PUNCH CD study assessing a microbiota-based drug for recurrent Clostridium difficile infection (CDI). Methods.  A total of 34 patients enrolled in the PUNCH CD study received 1 or 2 doses of RBX2660 (microbiota suspension). Patients were requested to voluntarily submit stool samples at baseline and at 7, 30, and 60 days and 6 months after the last administration of RBX2660. Stool samples were tested for VRE using bile esculin azide agar with 6 µg/mL vancomycin and Gram staining. Vancomycin resistance was confirmed by Etest. Results.  VRE status (at least 1 test result) was available for 30 patients. All stool samples for 19 patients (63.3%, mean age 61.7 years, 68% female) tested VRE negative. Eleven patients (36.7%, mean age 75.5 years, 64% female) were VRE positive at the first test (baseline or 7-day follow-up). Of these patients, 72.7%, n = 8 converted to negative as of the last available follow-up (30 or 60 days or 6 months). Of the other 3: 1 died (follow-up data not available); 1 patient remained positive at all follow-ups; 1 patient retested positive at 6 months with negative tests during the interim. Conclusions.  Although based on a small sample size, this secondary analysis demonstrated the possibility of successfully converting a high percentage of VRE-positive patients to negative in a recurrent CDI population with RBX2660.

Undetected Vancomycin-Resistant Enterococcus Stool Colonization in a Veterans Affairs Hospital Using a Clostridium difficile–Focused Surveillance Strategy

2002 ◽  
Vol 23 (8) ◽  
pp. 474-477 ◽  
Author(s):  
Amy J. Ray ◽  
Claudia K. Hoyen ◽  
Sarbani M. Das ◽  
Elizabeth C. Eckstein ◽  
Curtis J. Donskey
Keyword(s):  
Clostridium Difficile ◽  
Veterans Affairs ◽  
Point Prevalence ◽  
Vancomycin Resistant Enterococcus ◽  
Surveillance Strategy ◽  
Stool Samples ◽  
Vancomycin Resistant

Abstract We examined the point prevalence of undetected vancomycin-resistant Enterococcus (VRE) stool colonization in an institution that screens stool samples submitted for Clostridium difficile testing. Of 112 patients not known to be colonized, 10 (9%) had rectal VRE colonization. A prospective algorithm was effective for identification of colonized patients.

scholarly journals Activity of a Novel Cyclic Lipopeptide, CB-183,315, against Resistant Clostridium difficile and Other Gram-Positive Aerobic and Anaerobic Intestinal Pathogens

2012 ◽  
Vol 56 (6) ◽  
pp. 3448-3452 ◽  
Author(s):  
D. R. Snydman ◽  
N. V. Jacobus ◽  
L. A. McDermott
Keyword(s):  
Staphylococcus Aureus ◽  
Clostridium Difficile ◽  
Vancomycin Resistant Enterococcus ◽  
Gram Positive ◽  
Content Type ◽  
Cyclic Lipopeptide ◽  
Excellent Activity ◽  
Intestinal Pathogens ◽  
Vancomycin Resistant ◽  
Aerobic And Anaerobic

ABSTRACTWe evaluated the activity of CB-183,315 againstClostridium difficile, including strains that are resistant to fluoroquinolones and metronidazole and with elevated MICs to vancomycin as well as other Gram-positive intestinal pathogens. The MICs of CB-183,315 against allC. difficileisolates were ≤1 μg/ml. CB-183,315 had greater activity than vancomycin and metronidazole againstC. difficileisolates and was more active than the comparators against vancomycin-resistant enterococcus (VRE). CB-183,315 also had excellent activity against methicillin-resistantStaphylococcus aureus(MRSA), otherClostridiumspp., andPeptostreptococcusspp.

Sign in / Sign up

Export Citation Format

Share Document